If you can spare a few minutes, please help us improve our website by completing this survey.
Friday, November 4, 2016, 12-1 pm
Koch Institute Auditorium (76-156)
Alan Ashworth, Ph.D., F.R.S.
President, UCSF Helen Diller Family Comprehensive Cancer Center
Senior Vice President for Cancer Services, UCSF Health
Professor of Medicine, Division of Hematology/Oncology, Department of Medicine
E. Dixon Heise Distinguished Professor in Oncology, UCSF
Alan Ashworth, Ph.D., F.R.S., is currently President of the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, a role he began in January 2015. He was previously Chief Executive of the Institute of Cancer Research (ICR) in London, United Kingdom.
In 1999 he was appointed the first Director of the Breakthrough Breast Cancer Research Centre where he was also Professor of Molecular Biology and leader of the Gene Function team. Professor Ashworth’s Directorship ended in January 2011 when was appointed Chief Executive of the ICR.
A translational biologist and laboratory researcher, Dr. Ashworth’s research focuses on understanding breast cancer genetics and applying what he learns to change the way patients are treated. He was a key part of the team that identified the BRCA2 breast cancer susceptibility gene, which is linked to an increased risk of some types of cancer. Ten years later, Dr. Ashworth found a way to kill BRCA1- and 2-related tumor cells by treating them with PARP inhibitors, which amplifies the damage caused by the broken DNA repair machinery in those cells. This exemplifies the genetic principle of synthetic lethality in cancer therapy.
Dr. Ashworth is an elected member of EMBO and the Academy of Medical Sciences and a Fellow of the Royal Society. He has been the recipient of a number of scientific prizes and awards including The European Society of Medical Oncology Lifetime Achievement Award, the David T. Workman Memorial Award of the Samuel Waxman Cancer Research Foundation and the Meyenburg Foundation’s Cancer Research Award and was the inaugural winner of the 2013 Basser Global Prize. He has also recently been selected as the recipient of the 2015 Genetics Society Medal.
The Judith Ann Lippard Memorial Lecture was established in 2014 in memory of Judy Lippard, the wife of Stephen J. Lippard, the Arthur Amos Noyes Professor of Chemistry at MIT. Judy died of endometrial cancer on September 9, 2013. Steve, Josh, and Alex Lippard, together with countless friends, students, and colleagues created the lectureship to honor Judy’s memory and celebrate her remarkable love of life.
The creation of the Judith Ann Lippard Lectureship was inspired by a similar lecture, created in 1974 in memory of Judy’s and Steve’s eldest son, Andrew, who died from a neurological disorder at age 7. Over time, the Andrew Mark Lippard Lecture at Columbia University has become one of the preeminent neurology lectures in the world.
The Judith Ann Lippard Lectureship will bring together the most innovative minds in cancer research from a variety of disciplines—biology, chemistry, engineering, clinical medicine—and features individuals whose research has the possibility to change the face of cancer. The Lippard Lecture will also unite two extraordinary cancer centers—MIT’s Koch Institute and the Massachusetts General Hospital Cancer Center. In addition to the formal lecture at MIT, the honorand will not only deliver Grand Rounds at MGH, but will also spend time with trainees, researchers, and physician-scientists at both institutions, thus inspiring the best and brightest young minds to advance cancer therapies.
Tyler Jacks, PhD
Stephen J. Lippard, PhD, ex officio
Jonathan Rosand, MD, MSc
Phillip A. Sharp, PhD
To join the Lippard family in celebrating Judy's life and legacy, please contact Lisa Schwarz, Managing Director of Development, Koch Institute for Integrative Cancer Research at MIT: 617-324-7399; email@example.com, or give online.